Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2017 08:00 ET | Source: MEDITE Cancer Diagnostics, Inc.

MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director

ORLANDO, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers...
November 14, 2017 17:25 ET | Source: MEDITE Cancer Diagnostics, Inc.

MEDITE Cancer Diagnostics Reports 2017 Third Quarter Financial Results

ORLANDO, Fla., Nov. 14, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers...
November 08, 2017 08:31 ET | Source: MEDITE Cancer Diagnostics, Inc.

MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer

ORLANDO, Fla., Nov. 08, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers...
October 03, 2017 07:05 ET | Source: MEDITE Cancer Diagnostics, Inc.

MEDITE Cancer Diagnostics Reports Closing of $5.4 Million Private Financing, Providing Working Capital to Drive Commercial Plan Execution

ORLANDO, Fla., Oct. 03, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers...
August 14, 2017 17:00 ET | Source: MEDITE Cancer Diagnostics

MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results

ORLANDO, FL--(Marketwired - Aug 14, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company"), specializing in the development, manufacturing and marketing of molecular biomarkers and...
July 27, 2017 08:00 ET | Source: MEDITE Cancer Diagnostics

MEDITE Cancer Diagnostics to Launch SureCyte(TM) C1 Stain Globally at the 29th European Congress of Pathology

ORLANDO, FL--(Marketwired - Jul 27, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical...
May 10, 2017 09:01 ET | Source: MEDITE Cancer Diagnostics, Inc.

MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations

ORLANDO, FL--(Marketwired - May 10, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company") specializing in the development, manufacturing and marketing of molecular biomarkers and...
April 28, 2017 09:01 ET | Source: MEDITE Cancer Diagnostics, Inc.

MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations

ORLANDO, FL--(Marketwired - Apr 28, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company") specializing in the development, manufacturing and marketing of molecular biomarkers and...
April 27, 2017 16:01 ET | Source: MEDITE Cancer Diagnostics, Inc.

MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial Officer

ORLANDO, FL--(Marketwired - Apr 27, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company"), specializing in the development, manufacturing, and marketing of molecular biomarkers and...
March 07, 2017 09:29 ET | Source: MEDITE Cancer Diagnostics

MEDITE Cancer Diagnostics Appoints Eric M. Goehausen to Board of Directors

ORLANDO, FL--(Marketwired - Mar 7, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) ("MEDITE" or the "Company"), a medical technology company specializing in the development, engineering,...